Form 4: Stereotaxis Director Nachum Shamir Granted 43,668 Restricted Share Units

Stereotaxis, Inc. Director and 10% Owner Nachum Shamir was granted 43,668 restricted share units, increasing his beneficial ownership to 89,276 shares.

Summary

• Nachum Shamir, a Director and 10% Owner of Stereotaxis, Inc. (STXS), was granted 43,668 restricted share units (RSUs) on July 1, 2025.
• Each restricted share unit represents the right to receive one share of common stock.
• The RSUs were granted at a price of $0, indicating they are part of an equity compensation or incentive plan.
• Following this transaction, Nachum Shamir's total direct beneficial ownership in Stereotaxis, Inc. increased to 89,276 shares of common stock.
• The restricted share units vest on the earliest of: the fifth anniversary of the award date, the date on which the director's service on the board terminates, or a Change of Control as defined in the award documents.

Sentiment

Score: 7

Explanation: The grant of restricted share units to a director and 10% owner is generally a positive signal, indicating alignment of interests and long-term commitment. It's a routine compensation event rather than a major strategic announcement, hence a moderately positive score.

Positives

• The grant of restricted share units to a director and 10% owner aligns management and significant shareholder interests with the company's long-term performance.
• The increase in beneficial ownership to 89,276 shares demonstrates continued commitment from a key insider.

Risks

• The vesting of the restricted share units is contingent on future events, including continued service or a change of control, which introduces a degree of uncertainty regarding the ultimate realization of these shares.

Future Outlook

The vesting schedule for the restricted share units indicates a long-term incentive structure, with vesting contingent on the fifth anniversary of the award date, termination of director service, or a Change of Control, aligning the director's interests with the company's future performance and strategic goals.

Industry Context

This Form 4 filing reflects a standard practice of granting equity compensation to directors, a common mechanism in the healthcare technology industry to align leadership incentives with shareholder value creation and long-term strategic goals. Such grants are typical for publicly traded companies like Stereotaxis, Inc., which operates in the medical robotics and navigation sector.

Comparison to Industry Standards

• Equity grants to directors, particularly in the form of restricted share units, are a common compensation practice across the medical device and healthcare technology sectors.
• Companies like Intuitive Surgical (ISRG) and Medtronic (MDT) also utilize similar equity-based incentives to retain and motivate key personnel.
• The vesting conditions, tied to service and potential change of control, are standard for ensuring long-term commitment and incentivizing strategic outcomes. The specific value of the grant would need to be compared against peer group director compensation disclosures to assess if it is within industry norms, but the mechanism itself is standard.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director and 10% owner aligns his interests with long-term shareholder value creation. The increase in beneficial ownership may be viewed positively as a sign of confidence.
• Management/Employees: This transaction is specific to a director's compensation and does not directly impact other employees or management, though it reflects the company's equity compensation practices.

Next Steps

• The restricted share units will vest on the earliest of the fifth anniversary of the award date (July 1, 2030), termination of the director's service on the board, or a Change of Control.

Key Dates

Keywords

Stereotaxis, STXS, Form 4, Insider Transaction, Restricted Share Units, RSU, Beneficial Ownership, Director Compensation, Equity Grant, Nachum Shamir